Medtech Reimbursement In The EU: The Early Bird Catches The Worm
There is no “one size fits all” approach to gaining reimbursement in Europe – medtech companies must tailor their strategies to individual markets. A panel of reimbursement specialists at the recent IN3 meeting in Dublin advised companies planning market entry to do their homework, keep up to date with market developments, and think early.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.